GlassScriptPhysician profile
Stephen P Coppa
NPI 1376540500
$4,240.68
in general payments reported to CMS, 2019-2025
26 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $511 · 2021: $637 · 2022: $542 · 2023: $715 · 2024: $749 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.07 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $557.81 | 2021-2025 | |
| Lilly USA, LLC | $499.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $426.10 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $404.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $388.89 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $370.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $350.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $342.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $167.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $163.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.79 | 2020-2022 | |
| Abbott Laboratories | $76.55 | 2021-2023 | Proclaim, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $63.09 | 2019-2021 | |
| Ibsa Pharma INC. | $47.41 | 2020-2021 | |
| Boston Scientific Corporation | $40.22 | 2019-2024 | Wavewriter Alpha Prime 16 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.77 | 2021-2022 | |
| Philips North America LLC | $26.94 | 2023-2025 | Extended Holter |
| Janssen Pharmaceuticals, INC | $26.86 | 2020 | |
| Allergan, INC. | $26.86 | 2019-2020 | |
| Optinose US, INC. | $24.22 | 2022 | |
| Sanofi Pasteur INC. | $18.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.25 | 2023 | Austedo |
| Daiichi Sankyo INC. | $16.43 | 2023 | Injectafer |
| Nevro Corp. | $15.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2021 | |
| Axsome Therapeutics, INC. | $14.05 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Coppa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.